Steven Shoelson, M.D., Ph.D., Head of the Section on Pathophysiology and Molecular Pharmacology and Professor of Medicine at Harvard Medical School, says that inflammation is a factor in the development of type 2 diabetes.
The scientists became interested in studying salsalate, an anti-inflammatory drug, to lower blood glucose levels and the researcher Steven Shoelson targeted Type 2 Diabetes using anti-inflammatory drug Salsalate.
After 48 weeks of treatment, it was observed that patients in the salsalate group required fewer additional diabetes medications to control their blood sugar than patients in the placebo group.
Allison Goldfine, M.D., lead author and Head of the Section of Clinical, Behavioral and Outcomes Research, and an Associate Professor of Medicine at Harvard Medical School, said that “It’s exciting that salsalate is effective in lowering blood sugar”. They are of the opinion that “Salsalate may have an important role in diabetes treatment and may also help us learn more about how inflammation contributes to the development of type 2 diabetes.”
The salsalate group also showed improvements in markers associated with coronary risk.
1. a 9 percent reduction in triglycerides and
2. a 27 percent increase in adiponectin (a potentially cardioprotective protein from adipocytes)
3. Uric acid decreased 18 percent in the salsalate group
4. The reductions in these cardiovascular risk factors paralleled improved glycemia,
Down side of this application is that the salsalate group also exhibited modest increases in LDL cholesterol and urine albumin, and had a slight increase in weight, which can indicate negative effects on heart or kidney function.
Therefore, the task before the researchers is to find out whether salsalate is a safe drug for use as a diabetes medication.
Dr. Goldfine is currently leading a study, TINSAL-CVD, which is evaluating how salsalate affects coronary artery plaque volume in participants with established coronary artery disease. The results should be available in two years.
“Lets hope that at the end of the day the study will conclude an amicable risk/benefit ratio to use salsalate to treat diabetes,” because diabetes, obesity, inflammations are linked to Cancer (A Link Between Cancer and Diabetes?).
View the video presentation by Dr. Goldfine, M.D., lead author and Head of the Section of Clinical, Behavioral and Outcomes Research, and an Associate Professor of Medicine at Harvard Medical School.
Read more of this at Joslin Diabetes Center
Salsalate is a non-steroidal anti-inflammatory drug (NSAID). Salsalate is in a class of drugs called salicylates. Salsalate may work by inhibiting the production of and release of prostaglandins. Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab.
Salsalate is used to reduce pain and inflammation caused by conditions such as rheumatoid arthritis, osteoarthritis, and related rheumatic conditions. Salsalate is also recommended by physicians as an anti-inflammatory alternative to naproxen, and ibuprofen for patients that have had minor stomach bleeding or stomach upset. It has also been used as an alternative to narcotic pain medicine for people with spinal disc protrusion.
“In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.”
The Wall Street Journal Health Blog reported on research on using Salsalate to prevent or treat type II diabetes: “In a 20-patient, month-long study, the fasting glucose levels of those who took salsalate declined 13% compared with those who took a placebo. The results, published in the Feb. issue of Diabetes Care, suggest that the drug reduces blood sugar in obese adults who don’t have diabetes, apparently by making insulin work better.”Salsalate had been suggested as possible treatment for diabetes as early as 1876.The anti-inflammatory property of salsalate may reverse the chronic inflammation thought to be the cause of diabetes in the obese.